


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-21. Canceled.


22. (Currently Amended) Method of functionally stimulating the peripheral receptor CB₁ of cannabinoids treating a condition selected from a peripheral, somatic or autonomic neuropathies, multiple sclerosis, hypertrophic or cheloid cicatrization, psoriasis, urticaria, urticaria-angioedema syndrome, a pathology mediated by hyperreactivity of the vaginal or vulvo-vaginal canal, arthritis, a pathology mediated by hyperactivity of the bladder mucosa, breast tumor or prostate carcinoma, said method comprising administering a compound of general formula (I):



in which:


- a) R₁ is chosen from the group comprising hydrogen, linear or branched, saturated or unsaturated C1-C10 alkyl, C3-C7 cycloalkyl or C7-C10 arylalkyl;
- b) Y is chosen from the group comprising:
 - b1. hydrogen;

b2. a group of formula



in which $-\mathbf{R}_8\text{-}$ is a saturated, linear or branched C2-C6 alkylene radical and M is chosen from the group comprising $-\text{NH}_2$, acylamine, $-\text{NHR}_6$, $-\text{NR}_4\mathbf{R}_5$, $-\text{NR}_4\mathbf{R}_5\mathbf{R}_6\text{Z}^-$, which may be identical or different, and \mathbf{R}_4 , \mathbf{R}_5 and \mathbf{R}_6 , which may be identical or different, can be C1-C7 alkyl, alkenyl or arylalkyl radicals or \mathbf{R}_4 and \mathbf{R}_5 can form a cycloalkyl radical optionally containing hetero atoms such as $-\text{O}-$ and $-\text{NR}_{12}\text{-}$, in which \mathbf{R}_{12} is chosen from hydrogen and an alkyl, aralkyl or hydroxyalkyl radical preferably chosen from $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{CH}_2\text{-C}_6\text{H}_5$ and $-\text{CH}_2\text{CH}_2\text{OH}$ and Z^- is as defined below;

b3. a group of formula




in which \mathbf{R}_9 is a saturated or monounsaturated, linear or branched C1-C10 alkyl radical, or a cycloalkyl, arylalkyl or heterocyclic radical optionally substituted with one or more $-\text{OH}$, $-\text{COOH}$, $-\text{SO}_3\text{H}$, $-\text{NH}_2$, $-\text{NHR}_6$, $-\text{NR}_4\mathbf{R}_5$, $-\text{NR}_4\mathbf{R}_5\mathbf{R}_6\text{Z}^-$ groups, which may be identical or different, the groups \mathbf{R}_4 , \mathbf{R}_5 and \mathbf{R}_6 , which may be identical or different, being chosen from the group comprising C1-C7 alkyl, alkenyl and aralkyl radicals, or \mathbf{R}_4 and \mathbf{R}_5 can form a cycloalkyl radical which can comprise one or more hetero atoms $-\text{O}-$ and $-\text{NR}_{12}\text{-}$, in which \mathbf{R}_{12} is chosen from hydrogen and an alkyl, aralkyl or hydroxyalkyl radical chosen from $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{CH}_2\text{-C}_6\text{H}_5$ and $-\text{CH}_2\text{CH}_2\text{OH}$ and Z^- is as defined below,

b4. a -PO₃H₂, -SO₃H, or -P(OH)₂ group,

b5. a monosaccharide residue linked by an α - or β - glycoside bond,

b6. a group of formula



in which R₁₀ is a linear or branched, saturated or unsaturated C1-C10 alkyl or alkenyl radical, or a cycloalkyl or aralkyl radical optionally containing from 1 to 5 identical or different hetero atoms chosen from -S-, -O- and -N-, and optionally substituted with one or more -OH, -NH₂, -NH-CO-CH₃, -COOH, >C=O, H₂N-CO-NH-, NH=C(NH₂)-NH-, -NO₂, -OCH₃, -Cl, -Br, -F, -I, -OPO₃H₂, -OPO₂H₂, -OSO₃H, -OSO₃H, -SH, -SCH₃, -S-S-, -NHR₆, -NR₄R₅, -[⊕]NR₄R₅R₆Z⁻ groups, which may be identical or different, in which R₄, R₅ and R₆, which may be identical or different, can be C1-C7 alkyl, alkenyl or aralkyl radicals or R₄ and R₅ can form a cycloalkyl radical comprising one or more hetero atoms -O- and -NR₁₂⁻, in which R₁₂ is chosen from hydrogen and an alkyl, aralkyl or a hydroxyalkyl radical chosen from -CH₃, -C₂H₅, -CH₂-C₆H₅ and -CH₂CH₂OH and Z⁻ is as defined below,


c) R₃ is chosen from the group comprising hydrogen and linear or branched alkyl;

d) R is:

d1. carboxyl, -COOR₇, saturated or unsaturated cycloalkyl, polycyclic alkyl, aryl, heteroaryl, arylalkyl or C1-C35 alkyl, which is saturated or unsaturated with 1 to 6 double bonds, linear or branched and unsubstituted or substituted with one or more

residues chosen from the group comprising carboxyl, -COOR₇, hydroxyl, alkoxy, O-acylhydroxy, ketoalkyl, nitro, halo, -SH, alkylthio, alkyldithio, amino, mono- and dialkylamino, N-acylamino, -⁴NR₄R₅R₆Z⁻, in which R₄, R₅ and R₆, which may be identical or different, are chosen from the group comprising C1-C7 alkyl, C1-C7 alkenyl and arylalkyl and Z⁻ is an anion of a biologically compatible inorganic or organic acid ;

d2. a group of formula



in which R₁, R₃ and Y have the meanings given above and R₂ is a single bond or a linear or branched, saturated or unsaturated C1-C34 alkylene radical containing from 1 to 6 double bonds, a saturated or unsaturated cycloalkylene radical, an aryl, aralkyl or heterocyclic diradical, which is unsubstituted or substituted with one or more residues chosen from the group comprising carboxyl, -COOR₇, hydroxyl, alkoxy, O-acylhydroxy, alkylketo, nitro, halo, -SH, alkylthio, alkyldithio, amino, mono- and dialkylamino, N-acylamino, saturated or unsaturated cycloalkyl, aryl and heteroaryl; in which R₇ is a linear or branched C1-C20 alkyl group or an aralkyl group, enantiomers and diastereoisomers of the compounds of formula (I) and mixtures thereof, salts of the compounds of formula (I) with pharmaceutically acceptable acids and bases, and solvates thereof.

23. (Previously Presented) The method according to Claim 22, in which in the compound

of general formula (I):

- R₁ is methyl;
- Y is hydrogen or a saccharide group chosen from D- and L-ribose, D- and L-glucose, D- and L-galactose, D- and L-mannose, D-fructose, D- and L-glucosamine, D-galactosamine, D-mannosamine, glucuronic acid, sialic acid, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine, N-acetyl-D-mannosamine; or aminoethyl, dimethylaminoethyl, trimethylaminoethyl; or methylcarbonyl, phenylcarbonyl, pyridinocarbonyl, trimethoxyphenylcarbonyl, hemisuccinoyl, aminomethylcarbonyl, aminopropyl-carbonyl, dimethylaminomethylcarbonyl, trimethylamino-methylcarbonyl, sulphonophenylcarbonyl; or phosphate, sulphonate; or ethyloxycarbonyl, benzyloxycarbonyl, isobutyloxycarbonyl, dimethylaminopropyloxycarbonyl, trimethylaminoethyloxycarbonyl;
- R₃ is hydrogen.

24. (Previously Presented) The method according to Claim 22, in which R or R₂, together with the terminal -CO- groups to which they are attached, are, respectively, mono- or diacyl radicals of an acid chosen from the group comprising palmitic acid, arachidonic acid, oxalic acid, fumaric acid, maleic acid, azelaic acid, succinic acid, traumatic acid, muconic acid, cromoglycolic acid, malic acid, tartaric acid, aspartic acid, glutamic acid and oleic acid.

25. (Previously Presented) The method according to Claim 23, in which R or R₂, together with the terminal -CO- groups to which they are attached, are, respectively,

mono- or diacyl radicals of an acid chosen from the group comprising palmitic acid, arachidonic acid, oxalic acid, fumaric acid, maleic acid, azelaic acid, succinic acid, traumatic acid, muconic acid, cromoglycolic acid, malic acid, tartaric acid, aspartic acid, glutamic acid and oleic acid.

26. (Previously Presented) The method according to Claim 22, in which the compound of formula (I) is chosen from:


- N-(4-hydroxy-3-methoxybenzyl)oleylamide;
- N-(4-hydroxy-3-methoxybenzyl)palmitoylamide;
- N-(4-hydroxy-3-methoxybenzyl)arachidonoylamide;
- N,N'-bis(4-hydroxy-3-methoxybenzyl)nonanediamide.

27.-50. Canceled.

51. (Previously Presented) The method according to claim 22, in which Z⁻ is chosen from hydrochloric acid, sulphuric acid, phosphoric acid, methanesulphonic acid, benzenesulphonic acid, p-toluenesulphonic acid, acetic acid, succinic acid, fumaric acid, lactic acid, gluconic acid, citric acid, glucuronic acid, maleic acid and benzoic acid.

52. (Currently Amended) Method of functionally stimulating the peripheral receptor CB1 of cannabinoids treating a condition selected from a peripheral, somatic or autonomic neuropathies, multiple sclerosis, hypertrophic or cheloid cicatrization, psoriasis, urticaria, urticaria-angioedema syndrome, a pathology mediated by hyperreactivity of the vaginal or vulvo-vaginal canal, arthritis, a pathology mediated by hyperactivity of the bladder mucosa, breast tumor or prostate carcinoma, said method

comprising administering a compound of general formula (I):




in which:

a) R₁ is chosen from the group comprising hydrogen, linear or branched, saturated or unsaturated C1-C10 alkyl, C3-C7 cycloalkyl or C7-C10 arylalkyl;

b) Y is chosen from the group comprising:


b1. hydrogen;

b2. a group of formula



in which -R₈- is a saturated, linear or branched C2-C6 alkylene radical and M is chosen from the group comprising -NH₂, acylamine, -NHR₆, -NR₄R₅, $^{\oplus}\text{NR}_4\text{R}_5\text{R}_6\text{Z}^-$, which may be identical or different, and R₄, R₅ and R₆, which may be identical or different, can be C1-C7 alkyl, alkenyl or arylalkyl radicals or R₄ and R₅ can form a cycloalkyl radical optionally containing hetero atoms such as -O- and -NR₁₂- , in which R₁₂ is chosen from hydrogen and an alkyl, aralkyl or hydroxyalkyl radical preferably chosen from -CH₃, -C₂H₅, -CH₂-C₆H₅ and -CH₂CH₂OH and Z is as defined below;

b3. a group of formula




in which R₉ is a saturated or monounsaturated, linear or branched C1-C10 alkyl radical, or a cycloalkyl, arylalkyl or heterocyclic radical optionally substituted with one or more -OH, -COOH, -SO₃H, -NH₂, -NHR₆, -NR₄R₅, -[⊕]NR₄R₅R₆Z⁻ groups, which may be identical or different, the groups R₄, R₅ and R₆, which may be identical or different, being chosen from the group comprising C1-C7 alkyl, alkenyl and aralkyl radicals, or R₄ and R₅ can form a cycloalkyl radical which can comprise one or more hetero atoms -O- and -NR₁₂-, in which R₁₂ is chosen from hydrogen and an alkyl, aralkyl or hydroxyalkyl radical chosen from -CH₃, -C₂H₅, -CH₂-C₆H₅ and -CH₂CH₂OH and Z⁻ is as defined below,

b4. a -PO₃H₂, -SO₃H, or -P(OH)₂ group,

b5. a monosaccharide residue linked by an α- or β- glycoside bond,

b6. a group of formula



in which R₁₀ is a linear or branched, saturated or unsaturated C1-C10 alkyl or alkenyl radical, or a cycloalkyl or aralkyl radical optionally containing from 1 to 5 identical or different hetero atoms chosen from -S-, -O- and -N-, and optionally substituted with one or more -OH, -NH₂, -NH-CO-CH₃, -COOH, >C=O, H₂N-CO-NH-, NH=C(NH₂)-NH-, -NO₂, -OCH₃, -Cl, -Br, -F, -I, -OPO₃H₂, -OPO₂H₂, -OSO₃H, -OSO₃H, -SH, -SCH₃, -S-S-,


-NHR₆, -N R₄R₅, -[⊕]NR₄R₅R₆Z⁻ groups, which may be identical or different, in which R₄, R₅ and R₆, which may be identical or different, can be C1-C7 alkyl, alkenyl or aralkyl radicals or R₄ and R₅ can form a cycloalkyl radical comprising one or more hetero atoms -O- and -NR₁₂- , in which R₁₂ is chosen from hydrogen and an alkyl, aralkyl or a hydroxyalkyl radical chosen from -CH₃, -C₂H₅, -CH₂-C₆H₅ and -CH₂CH₂OH and Z⁻ is as defined below,

c) R₃ is chosen from the group comprising hydrogen and linear or branched alkyl;

d) R is:

d1. carboxyl, -COOR₇, saturated or unsaturated cycloalkyl, polycyclic alkyl, aryl, heteroaryl, arylalkyl or C1-C35 alkyl, which is saturated or unsaturated with 1 to 6 double bonds, linear or branched and unsubstituted or substituted with one or more residues chosen from the group comprising carboxyl, -COOR₇, hydroxyl, alkoxy, O-acylhydroxy, ketoalkyl, nitro, halo, -SH, alkylthio, alkyldithio, amino, mono- and dialkylamino, N-acylamino, -[⊕]NR₄R₅R₆Z⁻, in which R₄, R₅ and R₆, which may be identical or different, are chosen from the group comprising C1-C7 alkyl, C1-C7 alkenyl and arylalkyl and Z⁻ is an anion of a biologically compatible inorganic or organic acid;

d2. a group of formula



in which R₁, R₃ and Y have the meanings given above and R₂ is a single bond or a linear

or branched, saturated or unsaturated C1-C34 alkylene radical containing from 1 to 6 double bonds, a saturated or unsaturated cycloalkylene radical, an aryl, aralkyl or heterocyclic diradical, which is unsubstituted or substituted with one or more residues chosen from the group comprising carboxyl, -COOR₇, hydroxyl, alkoxy, O-acylhydroxy, alkylketo, nitro, halo, -SH, alkylthio, alkyldithio, amino, mono- and dialkylamino, N-acylamino, saturated or unsaturated cycloalkyl, aryl and heteroaryl; in which R₇ is a linear or branched C1-C20 alkyl group or an aralkyl group, enantiomers and diastereoisomers of the compounds of formula (I) and mixtures thereof, salts of the compounds of formula (I) with pharmaceutically acceptable acids and bases, and solvates thereof; provided R₁ and Y are not both H or -O-alkyl and H, respectively.

53. (Previously Presented) The method according to claim 52, in which Z⁻ is chosen from hydrochloric acid, sulphuric acid, phosphoric acid, methanesulphonic acid, benzenesulphonic acid, p-toluenesulphonic acid, acetic acid, succinic acid, fumaric acid, lactic acid, gluconic acid, citric acid, glucuronic acid, maleic acid and benzoic acid.